N-3 fatty acids for improvement in Respiratory Outcomes - the N3RO Trial

This dataset includes 1273 very preterm infants born at less than 29 weeks of gestation recruited into the N3RO trial. Infants were randomised to receive an enteral DHA or control emulsion from the first 3 days of enteral feeds until 36 weeks postmenstrual age or discharge home, whichever occurred first. Baseline clinical and sociodemographic characteristics of the infants and their families were collected, along with blood spot samples for fatty acid analysis at baseline and 36 weeks postmenstrual age. The primary outcome was bronchopulmonary dysplasia, as assessed by the requirement for supplemental oxygen and/or assisted ventilation at 36 weeks postmenstrual age. Also available are data on secondary clinical outcomes collected during the neonatal hospitalisation. File type is .PDF.